RZLT — Rezolute, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1509261 ·
Last close
$3.30
Market Cap
$317.76M
52W High
$3.87
52W Low
$2.29
ADV30
1,284,145
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -17,366,000 | -16,171,000 | 125,459,000 | 11,236,000 | 8,625,000 |
| Dec 2025 | 0 | — | -24,221,000 | -22,774,000 | 138,629,000 | 11,944,000 | 10,631,000 |
| Sep 2025 | 0 | — | -19,817,000 | -18,150,000 | 158,664,000 | 9,098,000 | 11,496,000 |
| Jun 2025 | 0 | — | -25,850,000 | -24,390,000 | 175,490,000 | 94,107,000 | 13,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,149,000
Investing CF
$-22,276,000
Financing CF
$102,437,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-444,780,000
Inventory
—
Receivables
—
ST Investments
$120,994,000
EBIT TTM
$-89,911,000
Pretax Income TTM
$-84,228,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -79,894,000 | -74,412,000 | 175,490,000 | 13,363,000 | — | -69,075,000 |
| Jun 2024 | 0 | -70,423,000 | -68,459,000 | 132,737,000 | 11,734,000 | — | -57,368,000 |
| Jun 2023 | 0 | -55,990,000 | -51,787,000 | 123,721,000 | 7,549,000 | — | -44,481,000 |
| Jun 2022 | 0 | -41,612,000 | -41,060,000 | 152,420,000 | 2,949,000 | — | -39,616,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TENX | TENAX THERAPEUTICS, INC. | $317.77M | $11.98 | — |
| SLN | Silence Therapeutics plc | $313.64M | $6.64 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $312.90M | $5.49 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $327.58M | $3.00 | — |
| IRD | Opus Genetics, Inc. | $332.91M | $4.09 | — |
News headlines (Yahoo Finance, 1h cache)
High Growth Tech Stocks in US for May 2026
2026-05-14 11:38 · Yahoo
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Rezolute to Participate in Upcoming Investor Conferences
2026-05-11 11:00 · Yahoo
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
2026-05-01 16:15 · Yahoo
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
2026-04-21 11:00 · Yahoo
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
2026-04-06 21:40 · Yahoo
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
2026-03-25 14:08 · Yahoo
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
2026-03-24 11:00 · Yahoo
XOMA Royalty Q4 Earnings Call Highlights
2026-03-18 23:20 · Yahoo
Rezolute to Participate in the Citizens Life Sciences Conference
2026-03-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.